Proceedings of the National Academy of Sciences · 2017 · 56 citations · 21 references
Life SciencesMolecular BiologyPathologyEpigeneticsGene ExpressionInflammationAntifibrotic TherapyChronic Liver DiseaseFibrosisHepatic FibrosisHepatic PathophysiologyMicrorna BiologyActivated Hepatic Stellate CellsFibrotic ChangeHepatic Stellate Cell BiologyLiver Fibrosis ProgressionLiver Stellate Cell ActivationMicrorna Regulation Of FibrogenesisPathogenesis Of SchistosomiasisSchistosomiasis Pathology
Significance Hepatic fibrosis is the final common pathological outcome of many chronic liver diseases and occurs when hepatic stellate cells (HSCs) are activated to become fibrogenic myofibroblasts. To date, there are still no approved antifibrotic therapies. Accumulating evidence suggests that targeting the deregulated miRNAs could mitigate disease outcomes. In this study, using a well-studied model of human schistosomiasis, we show that elevated miR-351 promotes the activation of HSCs after infection by targeting the vitamin D receptor, and inhibition of miR-351 in the liver mediated by rAAV8 protects the host from lethal infection by alleviating hepatic fibrosis. This study provides insights into the mechanisms that result in schistosomiasis-related hepatic fibrosis and targets of intervention for schistosomiasis and other fibrotic diseases.
21
The Lancet · 2014 · 2.4K citations · Full text
A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response
Ning Ding, Ruth T. Yu, Nanthakumar Subramaniam et al. · Cell · 2013 · 620 citations · Full text